Hess compared two doses of temsirolimus (a mTOR inhibitor) with investigator choice in mantle cell lymphoma and found that the higher dose of temsirolimus significantly improved the PFS compared with the tumour response rate of the lower dose of temsirolimus but significantly increased the number of grade 3 and 4 adverse events[74]. Here, MTOR is linked to mantle cell lymphoma.